Watch this session if you wish to learn why the 2019 guidelines were revised, how to apply the updated recommendations in clinical settings through case examples, and the criteria for selecting patients with left main stenosis for PCI versus CABG.
The session includes detailed presentations on...

This session delves into the challenges of dealing with uncrossable and heavily calcified coronary lesions. It features a variety of cases showcasing the use of specialized techniques and tools, such as the excimer laser, to overcome these obstacles. The session emphasizes the importance of troubleshooting, utilizing...

This session examines various complications that can arise during mitral valve interventions, such as iatrogenic aortic root perforation, unexpected leakage, and other challenging scenarios. The presenters share their experiences in managing these complications and the strategies they employed to address them. The session emphasizes the importance...

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...